← Leaderboards
Donna Lucy Livant
University Of Michigan At Ann Arbor
$2,462,470
Attributed
$2,462,470
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $269.8K · FY2006–13$500K$375K$250K$125K$0
'06
'07
'08
'09
'10
'11
'12
'13
Funding mix
By agency
NIH$2,462,470 · 3
By mechanism
R01$1,314,840 · 1
P50$992,130 · 1
R03$155,500 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Michigan At Ann Arbor
Same institution · by research overlap
- Melanie S Sanford$8,164,908
- Benjamin L Margolis$9,338,343
- Randall K Ten Haken$3,907,299
- Juanita L Merchant$22,602,061
- Michael D Morris$13,293,722
Others in their field
Top investigators on “Peptides”
- David M Nathan · Massachusetts Institute Of Technology$118,672,444
- John M Lachin · George Washington University$118,672,444
- David Heimbrook · Leidos Biomedical Research, Inc.$91,429,616
- Michael W Weiner · Northern California Institute Res &Educ$78,425,041
- Paul S. Aisen · Cognition Therapeutics, Inc.$69,846,203
- Rolf Apweiler · European Molecular Biology Laboratory$56,677,991
Research focus
PeptidesPublishingInhibitor/AntagonistPathway InteractionsPolylysinePreventDisease ProgressionInduction Of ApoptosisIn VivoNeoplasm MetastasisPlayBasement MembraneBinding (Molecular Function)Pre-Clinical ModelCancer CellAcetyl-Prolyl-Histidyl-Seryl-Cysteinyl-AsparaginamideApoptosisExtravasationIntegrinsIn VitroMalignant Neoplasm Of ProstateMediatingCellsReceptor
Grant awards (13)
PhScN as a Potent Agent for Use with Radiation in Pancreatic Cancer$77,750
R03 · FY2013 · CA · contact PI
PhScN as a Potent Agent for Use with Radiation in Pancreatic Cancer$77,750
R03 · FY2012 · CA · contact PI
PHSCN Therapies to Prevent Prostate Cancer Progression$261,260
R01 · FY2010 · CA · contact PI
PHSCN Therapies to Prevent Prostate Cancer Progression$261,260
R01 · FY2009 · CA · contact PI
PHSCN Therapies to Prevent Prostate Cancer Progression$261,260
R01 · FY2008 · CA · contact PI
PHSCN Therapies to Prevent Prostate Cancer Progression$261,260
R01 · FY2007 · CA · contact PI
PHSCN Therapies to Prevent Prostate Cancer Progression$269,800
R01 · FY2006 · CA · contact PI
PHSCN AND RELATED PEPTIDES--NOVEL ANTI-INVASIVE AND ANTI-METASTATIC AGENTS$165,355
P50 · FY2002 · CA
PHSCN AND RELATED PEPTIDES--NOVEL ANTI-INVASIVE AND ANTI-METASTATIC AGENTS$165,355
P50 · FY2001 · CA
PHSCN AND RELATED PEPTIDES--NOVEL ANTI-INVASIVE AND ANTI-METASTATIC AGENTS$165,355
P50 · FY2000 · CA
PHSCN AND RELATED PEPTIDES--NOVEL ANTI-INVASIVE AND ANTI-METASTATIC AGENTS$165,355
P50 · FY2000 · CA
PHSCN AND RELATED PEPTIDES--NOVEL ANTI-INVASIVE AND ANTI-METASTATIC AGENTS$165,355
P50 · FY2000 · CA
PHSCN AND RELATED PEPTIDES--NOVEL ANTI-INVASIVE AND ANTI-METASTATIC AGENTS$165,355
P50 · FY2000 · CA